Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients

Journal of the American College of Cardiology

Volumn 65, Issue 7, 2015, Pages 657-665

  Bayés Genís, Antoni ^a,b   Barallat, Jaume ^a,b   Galán, Amparo ^a,b   De Antonio, Marta ^a,b   Domingo, Mar ^a   Zamora, Elisabet ^a,b   Urrutia, Agustín ^a,b   Lupón, Josep ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

B type natriuretic peptide; prognosis; survival

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; MEMBRANE METALLOENDOPEPTIDASE; MINERALOCORTICOID ANTAGONIST; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; DISEASE ASSOCIATION; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITALIZATION; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MEMBRANE METALLOENDOPEPTIDASE BLOOD LEVEL; OUTCOME ASSESSMENT; OUTPATIENT; PREDICTION; REFERENCE VALUE; BLOOD; COMPLICATION; HEART STROKE VOLUME; MIDDLE AGED; MORTALITY; RISK FACTOR; SURVIVAL RATE;

AGED; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NEPRILYSIN; RISK FACTORS; STROKE VOLUME; SURVIVAL RATE;

EID: 84922822387     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.11.048     Document Type: Article

References (26)

1. S.L. Stephenson, and A.J. Kenny The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11 Biochem J 243 1987 183 187
2. A.J. Kenny, A. Bourne, and J. Ingram Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11 Biochem J 291 1993 83 88
3. J. Vijayaraghavan, A.G. Scicli, O.A. Carretero, C. Slaughter, C. Moomaw, and L.B. Hersh The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase) J Biol Chem 265 1990 14150 14155
4. O. Vardeny, T. Tacheny, and S.D. Solomon First-in-class angiotensin receptor NEP inhibitor in heart failure Clin Pharmacol Ther 94 2013 445 448
5. L.M. Ruilope, A. Dukat, M. Böhm, Y. Lacourcière, J. Gong, and M.P. Lefkowitz Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and NEP: a randomised, double-blind, placebo controlled, active comparator study Lancet 375 2010 1255 1266
6. S.D. Solomon, M. Zile, B. Pieske for the Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators The angiotensin receptor NEP inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial Lancet 380 2012 1387 1395
7. J.J. McMurray, M. Packer, A.S. Desai on behalf of the PARADIGM-HF Committee and Investigators Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) Eur J Heart Fail 15 2013 1062 1073
8. E.G. Erdös, and R.A. Skidgel Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones FASEB J 3 1989 145 151
9. V. Maguer-Satta, R. Besançon, and E. Bachelard-Cascales Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer Stem Cells 29 2011 389 396
10. Y. Komada, S. Peiper, B. Tarnowski, S. Melvin, H. Kamiya, and M. Sakurai Shedding of the common acute lymphoblastic leukemia antigen (CALLA) by lymphoblastoid cell lines Leuk Res 10 1986 665 670
11. B. Malfroy, W.J. Kuang, P.H. Seeburg, A.J. Mason, and P.R. Schofield Molecular cloning and amino acid sequence of human enkephalinase (neutral endopeptidase) FEBS Lett 229 1988 206 210
12. S. Kuruppu, N.W. Rajapakse, D. Minond, and A.I. Smith Production of soluble NEP by endothelial cells Biochem Biophys Res Commun 446 2014 423 427
13. Y. Liu, C. Studzinski, T. Beckett, M.P. Murphy, R.L. Klein, and L.B. Hersh Circulating NEP clears brain amyloid Mol Cell Neurosci 45 2010 101 107
14. A. Bayes-Genis, M. de Antonio, and A. Galán Combined use of high sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure Eur J Heart Fail 14 2012 32 38
15. E. Zamora, J. Lupón, and J. Vila Estimated glomerular filtration rate and prognosis in heart failure: value of the Modification of Diet in Renal Disease-4, Chronic Kidney Disease Epidemiology Collaboration, and Cockcroft-Gault formulas J Am Coll Cardiol 59 2012 1709 1715
16. C. Oefner, A. D'Arcy, M. Hennig, F.K. Winkler, and G.E. Dale Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon J Mol Biol 296 2000 341 349
17. K.N. Luckenbill, R.H. Christenson, and A.S. Jaffe Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage Clin Chem 54 2008 619 621
18. A. Bayes-Genis, M. de Antonio, and J. Vila Head-to-head comparison of 2 fibrosis biomarkers for long-term heart failure risk stratification: ST-2 versus galectin-3 J Am Coll Cardiol 63 2014 158 166
19. J. Sinisalo, F. Fyhrquist, M. Syrjälä, and M.S. Nieminen Stimulated release of endothelin-converting enzyme is simultaneous with tissue-type plasminogen activator and decrease in coronary heart disease Scand Cardiovasc J 36 2002 100 104
20. R. Kakkar, and R.T. Lee The IL-33/ST2 pathway: therapeutic target and novel biomarker Nat Rev Drug Discov 7 2008 827 840
21. C.J. Ferro, J.C. Spratt, W.G. Haynes, and D.J. Webb Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo Circulation 97 1998 2323 2330
22. J.J. McMurray, M. Packer, A.S. Desai on behalf of the PARADIGM-HF Committees Investigators Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) Eur J Heart Fail 16 2014 817 825
23. J.N. Cohn, G. Tognoni for the Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675
24. L.R. Potter Natriuretic peptide metabolism, clearance and degradation FEBS J 278 2011 1808 1817
25. Y. Watanabe, K. Nakajima, Y. Shimamori, and Y. Fujimoto Comparison of the hydrolysis of the three types of natriuretic peptides by human kidney neutral endopeptidase 24.11 Biochem Mol Med 61 1997 47 51
26. S. Mangiafico, L.C. Costello-Boerrigter, I.A. Andersen, A. Cataliotti, and J.C. Burnett Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics Eur Heart J 34 2013 886 893c